Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
Danny Rischin(Peter MacCallum Cancer Centre), Grant A. McArthur(The University of Melbourne), Brian O’Sullivan(University of Toronto), Benjamin Solomon(Peter MacCallum Cancer Centre), Liz Kenny(Palo Alto University), Stephen B. Fox(Peter MacCallum Cancer Centre), Jimin Choi(Palo Alto University), Richard J. Young(Palo Alto University), Quynh‐Thu Le(Stanford University), Lester J. Peters(Peter MacCallum Cancer Centre), Richard Fisher(Princess Margaret Cancer Centre)
Cited by 741
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k